Xcout Intel
Core Biomedicine competitors & alternatives
The 12 closest competitors and alternatives to Core Biomedicine among biotechnology companies — ranked by similarity to what Core Biomedicine actually does, not by market-cap band.
Subscribe to see Core Biomedicine’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Core Biomedicine
Core Biomedicine is a preclinical-stage biotechnology and pharmaceutical manufacturing company pioneering lineage-based precision oncology therapeutics.
Core Biomedicine at a glance
Core Biomedicine is a biotechnology company. Its most recent funding round, Series A, raised $21M in July 2026. Xcout tracks 1 named person at Core Biomedicine, including Ping Zhu (Co-Founder and CEO).
Core Biomedicine leadership
- Ping ZhuCo-Founder and CEO
Core Biomedicine funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $21M | 10 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Core Biomedicine competitors
Ranked by semantic similarity — how close each company is to Core Biomedicine by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.
Biotech
AUM Biosciences is a clinical-stage biotechnology company that develops precision oncology therapeutics utilizing multi-faceted inhibition strategies to overcome cancer drug resistance. The company serves patients and the healthcare sector by advancing a targeted clinical pipeline designed to combat tumor evasion and treatment resistance.
Life Sciences
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
Similar biotechnology company
Tyra Biosciences is a biotechnology company headquartered in Carlsbad, California, that develops next-generation precision medicines.
Similar biotechnology company
DCx Biotherapeutics is a Canadian preclinical-stage biotechnology company developing precision oncology therapeutics and precision drug conjugates to target genetically defined cancers. The company focuses on addressing root drivers and key cellular interdependencies of cancer lesions.
Biotech
Alterome Therapeutics, Inc. is a clinical-stage precision oncology company headquartered in San Diego, California, founded in 2021. The privately held biotech firm focuses on developing targeted therapies to address genomically defined cancer drivers and intractable oncological targets.
Biotech
Frontier Medicines, Corp. is a precision medicine company focusing on drug development with offices in locations including South San Francisco, California, and Boston.
Similar biotechnology company
One Biosciences is a biotechnology company headquartered in Paris, France. It is driven by innovative scientists and biotech leaders focused on advancing precision medicine and novel therapies for patients.
Similar biotechnology company
Laguna Pharmaceuticals is a biotechnology company developing precision microbial immunotherapy platforms to treat various cancers, including high-risk leukemias and soft-tissue sarcomas. The company utilizes engineered, highly attenuated microbial vectors to activate and expand innate T cells directly within the body, aiming to overcome immune evasion by tumors.
Similar biotechnology company
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Similar biotechnology company
Tessellate Bio is a biotechnology company that develops precision oncology medicines by exploring synthetic lethal interactions beyond homologous recombination deficiency. The company integrates biomarker discovery and companion diagnostics into its research programs to create first-in-class treatments for hard-to-treat cancers.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Core Biomedicine and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Core Biomedicineand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →